MedTrace Logo

Hypomagnesemia and Its Association With Calcineurin Inhibitors Use in Renal Transplant Recipients

NCT05352880 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-12-14

No results posted yet for this study

Summary

To assess the prevalence and risk factors of hypomagnesemia and its association with calcineurin inhibitor use among Egyptian renal transplant recipients.

Conditions

  • Renal Transplantation; Complication

Interventions

DIAGNOSTIC_TEST

serum magnesium level, FEMg

Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC. Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg) . Detailed history taking, Thorough Systemic physical examination.

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Mohamed Mamdouh Elsayed, MD · lecturer

  • montasser M Zeid, MD · professor

  • Iman E El Gohary, MD · professor

  • shady Fouad Abouelnaga, MD · fellow

  • Fathyia A Elian, MBBCh · resident

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-10
Primary Completion
2022-07-30
Completion
2022-09-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05352880 on ClinicalTrials.gov